Supplements · Metabolic & Cardiometabolic
fenugreek decreases postprandial glucose
In plain terms: Does fenugreek seed lower blood sugar after meals?
Strong support Supplements 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.86
Yes, well-supported in people with diabetes or prediabetes, though it doesn't help cholesterol.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
22 support 0 contradict 1 tested null 2 mixed · 25 sources, 21 independent groups
What the evidence shows
Fenugreek (galactomannan-rich seed) lowers fasting and 2-h postprandial glucose and HbA1c in T2D/prediabetes (LDL & HOMA-IR null). Bread use limited by bitter/maple aroma at effective doses.
The evidence (25)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Robert 2016 · Eur J Nutr | RCT | supports | moderate | Fenugreek seed powder in buns/flatbreads reduced glycemic response and GI in healthy subjects. |
| Arooj 2024 · Food Sci Nutr | RCT | mixed | low | Fenugreek-containing chickpea pulao lowered postprandial blood glucose in T2D crossover trial. |
| Akhtar H et al 2025 · study_type: observational | observational | supports | low | Narrative review of fenugreek bioactive compounds and health benefits; states fenugreek seeds/alkaloids/saponins improve glucose metabolism, insulin release, and lower blood glucose (no pooled effect sizes). |
| Shakil S et al 2024 · study_type: meta-analysis | meta-analysis | supports | low | Systematic review + meta-analysis of RCTs (fenugreek vs control in T2D) found fenugreek significantly reduced fasting blood glucose, HbA1c, and postprandial glucose (p<0.001) at 2-5g/day powder dose. |
| Al-Makhmari S et al 2025 · study_type: observational | observational | supports | low | Narrative review of Middle Eastern antidiabetic herbs (black seed, fenugreek, ginger, cinnamon, curcumin) citing RCTs/MAs; states fenugreek improved glycaemic control and lipid profiles across included human studies. |
| Chehregosha 2025 · Avicenna J Phytomed | meta-analysis | supports | moderate | RCT meta-analysis: fenugreek supplementation improved glycemic outcomes in pooled trials. |
| Saeed S et al 2026 · Preprints.org | RCT | supports | low | n=18 healthy adults, randomized crossover; 7.5% sprouted fenugreek chapatti vs control significantly reduced postprandial glucose and insulin responses (p<0.05) at 0/30/60/120 min. |
| Shabil 2023 · Medicina | meta-analysis | tested-null | low | [FT-verified] Shabil2023 syst review; consistent direction but small low-quality trial base |
| Kim J et al] # corrected 2026-08-17 from PubMed; was [(SR/MA 10 RCTs) 2023 · (SR/MA) | meta-analysis | supports | moderate | Significant drop in FBG, 2-hPG, HbA1c (n=706); HOMA-IR & LDL null |
| Robert 2014 · J Nutr Metab | RCT | supports | moderate | 5.5 g fenugreek with bread/rice cut postprandial glucose iAUC and increased satiety in overweight/obese. |
| Rao 2020 · J Med Food | observational | supports | low | Exploratory trial: fenugreek-based formulation improved glucose markers in diabetes. |
| Razon 2024 · J Diabetes Res | animal | supports | moderate | Fenugreek seed powder improved glycemic and lipid profiles in T2D rats via AMPK phosphorylation. |
| Gupta 2024 · Food Nutr Res | RCT | supports | moderate | Double-blind placebo-controlled RCT: patented fenugreek extract improved glycemic parameters. |
| Gong 2016 · J Ethnopharmacol | meta-analysis | supports | moderate | RCT MA: fenugreek improved fasting/postprandial glucose and lipids; trial quality mixed |
| Hannan 2003 · Br J Nutr | animal | supports | moderate | Fenugreek soluble dietary fibre reduced postprandial glucose and atherogenic lipids in T2D model rats. |
| Mazumdar S et al 2025 · study_type: mechanism | mechanism | supports | low | GC-MS/molecular docking/MD simulation study identifying AMPK-activating compounds in fenugreek and oyster mushroom extracts; in-silico/computational only, no in vitro or in vivo validation performed. |
| Deshpande PO et al 2025 · study_type: RCT | RCT | supports | moderate | n=21 (15 completers) T2D adults, randomized crossover CGM study; 30g FenuflakesTM (defatted fenugreek seed) reduced 24-h iAUC (p=0.02), MAGE (p=0.006), fasting glucose and HbA1c (p<0.05) vs control diet over 14 days. |
| Mate 2024 · J Food Sci | in-vitro | supports | moderate | Fenugreek seed extract inhibited pancreatic alpha-amylase and lowered predicted GI of wheat starch. |
| Das R et al 2025 · study_type: in-vitro | in-vitro | supports | low | Duplicate entry of the fenugreek α-amylase/luteolin-hesperetin study; same in-vitro inhibition kinetics (IC50 85.94 μM luteolin) on fenugreek-derived α-amylase. |
| Repin 2017 · Food Funct | RCT | mixed | moderate | Fenugreek gum among soluble fibres attenuated postprandial glycemia via viscosity/gastric emptying mechanisms. |
| Sarker DK et al 2024 · study_type: observational | observational | supports | low | Narrative review of fenugreek's antidiabetic mechanisms (preclinical + clinical); states clinical trials showed fenugreek seeds improved blood glucose, insulin resistance/sensitivity, and lipid profiles. |
| Neelakantan 2014 · Nutr J | meta-analysis | supports | moderate | [FT-verified] Neelakantan2014 10RCTs n=278 2h glucose -2.19 mmol/L but I2=71%, Egger p=.03 PUB-BIAS, mostly low-quality - pooled estimate unreliable |
| Silva Comilo G et al 2025 · study_type: in-vitro | in-vitro | supports | low | Pressurized-liquid-extracted, germinated fenugreek seed/sprout extracts showed high in-vitro inhibition of α-glucosidase (99%) and α-amylase (95%), indicating anti-hyperglycemic potential. |
| Chehregosha F et al 2024 · Research Square | meta-analysis | supports | moderate | Updated systematic review/meta-analysis of 26 RCTs: fenugreek significantly reduced FBS (WMD -16.75 mg/dL), 2h-PPG (WMD -22.28 mg/dL, I2=95.1%), HbA1c (-0.63), and insulin; HOMA-IR effect not significant. |
| Hassan MA et al 2026 · study_type: in-vitro | in-vitro | supports | low | Low-calorie biscuits with stevia + oat/fenugreek fibre (galactomannan/β-glucan) inhibited α-amylase (up to 33.87%) and α-glucosidase (up to 42.53%) in vitro; best formulation WB-6 used β-glucan not fenugreek galactomannan. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.